Pharmaceutical formulation is a multi-step process in which the active drug is mixed with all other ingredients, taking into account the factors of particle size, polymorphism, pH and solubility, and finally becomes the final drug.
New Delhi : The National Pharmaceutical Pricing Authority (NPPA), has announced the fixing of retail prices of several drugs in the country. NPPA, the drug price regulator, said that the agency has fixed the retail prices of 23 formulations, including drugs for the treatment of diabetes and hypertension. These new prices are fixed under the Drugs (Price Control) Directive 2013 based on the decision taken by the NPPA in its meeting on May 26, 2023.
Pharmaceutical formulation is a multi-step process in which the active drug is mixed with all other ingredients, taking into account the factors of particle size, polymorphism, pH and solubility, and finally becomes the final drug. This retail price of the formulation is calculated through a specific formula by the government.
According to the notification published by NPPA, the National Pharmaceutical Pricing Authority has set the price of diabetes drug Glicazide ER and Metformin Hydrochloride tablets at Rs 10.03 each. So this is going to be the new price of these medicines from now on. Similarly, the retail price of Telmisartan, Chlorthalidone and Cilnidipine tablets has been fixed at Rs 13.17 per tablet. Also, the retail price of pain relievers Trypsin, Bromelain, Rutoside Trihydrate and Diclofenac Sodium tablets has been fixed at Rs 20.51.
Apart from these issues, the NPPA said that ceiling prices of 15 prescribed formulations have been revised under the Drugs (Prices Control) Order, 2013 (NLEM 2022). It has also been decided to fix the ceiling price of two prescribed formulations.
The National Drug Price Regulatory Agency has fixed and revised the ceiling price of a particular formulation. NPPA regularly monitors the prices of controlled drugs in the country to keep them at a reasonable level. The agency is also tasked with recovering from consumers overcharges made by manufacturers for controlled drugs.
إرسال تعليق